Tag: Small Cell Lung Cancer

1. In patients with previously treated extensive-stage small-cell lung cancer (ES-SCLC), treatment with ifinatam deruxtecan (I-DXd) showed promising efficacy with ...

1. Royalty Pharma struck a deal worth up to 950 million dollars to buy into Amgen’s DLL3 directed bispecific for ...

Novo’s srRNA push expands cardiometabolic pipeline On August 28, Novo Nordisk announced a collaboration with Replicate Bioscience to pursue self ...

Click here to read this study in NEJM.  ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...

1. Median overall survival was 13.6 months in the tarlatamab group and 8.3 months in the chemotherapy group, with HR ...

Click here to read this study in NEJM.  ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...

1. Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. ...

1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo ...

Click here to read this study in NEJM.  ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...

1. The  progression-free survival in berzosertib with topotecan vs topotecan alone was not statistically significant, but the overall survival was ...